Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Adrienne Anderson

Physician Assistant, Medical Atlanta, GA Physician Assistant

NPI 1841738044 CMS profile 10424151

1800 Howell Mill Rd Nw Ste 450, Atlanta, GA 30318

Open in the dashboard

General payments

$24,926

954 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adrienne Anderson of Atlanta, GA is reported in the CMS Open Payments database as having received $24,926 across 954 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,766 149
2024 General $7,103 200
2023 General $4,511 199
2022 General $4,596 195
2021 General $4,949 211

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adrienne Anderson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Adrienne Anderson were reported at $3,766. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Adrienne Anderson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $4,949 $156 $41–$563 $132
2022 $4,596 $185 $55–$649 $149
2023 $4,511 $199 $58–$717 $160
2024 $7,103 $206 $62–$740 $164
2025 $3,766 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $2,801 41 payments
  2. Xeris Pharmaceuticals, Inc. $2,419 84 payments
  3. Tandem Diabetes Care, Inc. $2,392 11 payments
  4. Novo Nordisk Inc $2,325 150 payments
  5. Corcept Therapeutics $1,649 59 payments
  6. Insulet Corporation $1,338 36 payments
  7. Lilly USA, LLC $1,145 69 payments
  8. Dexcom, Inc. $1,096 42 payments
  9. Abbott Laboratories $1,070 68 payments
  10. Amgen Inc. $973 47 payments
  11. Other $7,717 347 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $22,645 946 payments
  2. Travel and Lodging $2,270 5 payments
  3. Education $10 3 payments
Products named General payments · program years 2021–2025
  1. MINIMED 780G $2,405 32 payments
  2. t:slim X2 Insulin Pump with Control-IQ $2,392 11 payments
  3. Korlym $1,649 59 payments
  4. Ozempic $1,395 107 payments
  5. RYBELSUS $1,375 104 payments
  6. Omnipod $1,338 36 payments
  7. GVOKE PFS $1,217 34 payments
  8. Dexcom G6 Transmitter $721 32 payments
  9. RECORLEV $698 32 payments
  10. FreeStyle Libre 3 $648 39 payments
  11. Other $15,765 723 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

1,506

Median for Physician Assistant: 241

Drug cost

$1,220,037

Median for Physician Assistant: $4,110

Branded share of claims

70.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 184 $301,012
Korlym Mifepristone Brand 20 $233,970
Mounjaro Tirzepatide Brand 132 $158,698
Rybelsus Semaglutide Brand 51 $100,760
Trulicity Dulaglutide Brand 52 $86,420
Jardiance Empagliflozin Brand 49 $60,882
Farxiga Dapagliflozin Propanediol Brand 31 $41,274
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 39 $40,831
Repatha Sureclick Evolocumab Brand 33 $26,364
Januvia Sitagliptin Phosphate Brand 24 $24,858

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RECORLEV
$480 — —
Korlym
$348 20 —
TZIELD
$235 — —
JARDIANCE
$222 49 —
UNITHROID
$199 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

954 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record